Molecular Partners´ collaboration partner Allergan exercises the third option for a DARPin® product candidate in ophthalmology
(WorldNews Switzerland)

Zurich-Schlieren, February 19, 2018. Molecular Partners AG (ticker: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies*, today announced that Allergan has exercised the third option to develop and commercialize DARPin® product candidates from its 2012 discovery alliance agreement with Molecular Partners. Upon the exercise of this option, Molecular Partners granted Allergan an exclusive license to the selected multi-DARPin® product candidates for use in ophthalmology. Building on abicipar with phase 3 wet AMD topline data expected in H2 2018, these novel multi-DARPin® product candidates further expand Molecular Partners` and Allergan`s...